Free Trial
NASDAQ:MTVA

MetaVia Q2 2025 Earnings Report

MetaVia logo
$0.64 0.00 (0.00%)
As of 04:00 PM Eastern

MetaVia EPS Results

Actual EPS
-$0.26
Consensus EPS
-$0.32
Beat/Miss
Beat by +$0.06
One Year Ago EPS
N/A

MetaVia Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

MetaVia Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Thursday, August 7, 2025
Conference Call Time
8:30AM ET

MetaVia Earnings Headlines

Musk’s Project Colossus could mint millionaires
I predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new millionaires than any tech advance in history. And for a limited time, you have the chance to claim a stake in this project, even though it’s housed inside Elon’s private company, xAI.
MetaVia Extends Phase 1 Trial for Obesity Drug
See More MetaVia Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like MetaVia? Sign up for Earnings360's daily newsletter to receive timely earnings updates on MetaVia and other key companies, straight to your email.

About MetaVia

MetaVia (NASDAQ:MTVA) is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc., formerly known as NeuroBo Pharmaceuticals Inc., is based in CAMBRIDGE, Mass.

View MetaVia Profile

More Earnings Resources from MarketBeat